hcp-home-02-pic

Image of a physician enrolling patients to Prolastin-C Liquid
Prolastin Direct Program logo – support for physicians and patients

Enroll your patients in the PROLASTIN DIRECT® program

With PROLASTIN DIRECT, the exclusive source for PROLASTIN-C LIQUID, you and your patients receive benefits beyond therapy with ongoing, comprehensive, personalized alpha-1 support.1

ENROLL A PATIENT

hcp-home-03-pic

Order your free AlphaID™ screening kits

Screen all your patients with COPD (chronic obstructive pulmonary disease) with the new AlphaID, a quick and easy cheek swab for screening your patients for alpha-1. AlphaID is completely free and confidential, from ordering to results.

ORDER YOUR FREE TEST KITS

Image of free Grifols AlphaKit tests for genetic COPD due to AAT deficiency

hcp-home-04-pic

Image of Prolastin-C Liquid bottle – the #1 prescribed alpha-1 therapy

Why PROLASTIN-C LIQUID?

PROLASTIN-C LIQUID provides a convenient, ready-to-infuse liquid formulation that has been proven to effectively raise alpha1-antitrypsin protein levels in patients with alpha-1.2

FIND OUT MORE

hcp-home-05-pic

Icon of DNA helix

About alpha-1

Alpha1-antitrypsin deficiency (alpha-1) is the #1 known genetic risk factor for COPD and may be a contributing cause for up to 3% of COPD cases in the United States.3,4

LEARN MORE ABOUT ALPHA-1

hcp_isi

IMPORTANT SAFETY INFORMATION

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use
  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
 

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

hcp_references-home

References:

1. Data on file, PROLASTIN DIRECT program. 2. PROLASTIN®-C LIQUID (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols. 3. World Health Organization. α1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415. 4. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with α1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.